Potential New First-Line Options for Unresectable Hepatocellular Carcinoma

Potential New First-Line Choices for Unresectable Hepatocellular Carcinoma

SAN FRANCISCO — An immunotherapy combination significantly improved overall survival (OS) versus sorafenib (Nexavar) as initial therapy for unresectable hepatocellular carcinoma (HCC), a large randomized trial showed. Patients treated with a single priming dose of tremelimumab followed by durvalumab (Imfinzi) had a median OS of 16.4 months as compared with 13.8 months with sorafenib. Survival…

Trending Medical and health breaking news Scientists find potential diagnostic and therapeutic target for lung cancer

Trending Medical and well being breaking information Scientists discover potential diagnostic and therapeutic goal for lung most cancers

Proposed model for the LCDR/hnRNP K/LAPTM5 axis promoting the pathogenesis of lung cancer. Credit: Gao Shan Chinese scientists recently reported the key role in tumor survival played by a histone-acetylation-regulated long noncoding RNA called lysosome cell death regulator (LCDR), providing a potential diagnostic and therapeutic target for lung cancer. Led by Prof. Gao Shan from…